HAYWARD, CA -- Metabolex, Inc. said that it raised a fourth round of venture capital, netting $32 million from a large group of VCs and private equity funds.
The company claims it has developed novel approaches to treatments for diabetes and related metabolic disorders and said it plans to use the funding proceeds to speed clinical testing of its dyslipidemia treatment.
Investors in the round were led by MPM BioEquities, and included AllianceBernstein, Deerfield Management, T. Rowe Price, Alta Partners, Bay City Capital, Biotech Turnaround Fund, Birchmere Ventures, Johnson & Johnson Development Corporation, KBC Funds, Merlin BioMed Group, Novo Ventures, VantagePoint Venture Partners, Venrock Partners and Versant Ventures.
|